PLSE PULSE BIOSCIENCES INC
Permanent stock page ↗Health Care · Russell 2000
Next earnings: not announced yet
What 9 analyst firms say about PULSE BIOSCIENCES INC: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
7 rated views · 9 analyst/firm records · 9 firms
Radar score
- Russell 2000 · Top Picks · 6MBelow the Radar threshold of 8050
- Russell 2000 · Safest consensus · 6MBelow the Radar threshold of 8065
Recent analyst activity · last 90 days
Our tracked history has 9 reports on PLSE from 8 analyst firms in the last 90 days (9 firms in the past year).
Comparing each firm's latest target with its previous one: 1 raised its price target, 1 left it unchanged and 4 have their first observed target in the past year.
No firm's latest available rating differs from its previous one.
Latest observed target change: Canaccord Genuity raised its target from $43.00 (set 10 Aug 2026) to $58.00 on 6 Oct 2026.
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| BTIG | Marie Thibault | Buy | 23 Sep 2026 | 70.00 USD |
| Canaccord Genuity | William Plovanic | Buy | 6 Oct 2026 | 58.00 USD |
| Freedom Capital | Unnamed analyst | Buy | 9 Sep 2026 | — |
| Freedom Capital Markets | Keith Hinton | Buy | 9 Sep 2026 | 73.00 USD |
| Mizuho | Anthony Petrone | — | 13 Oct 2026 | 55.00 USD |
| Needham | Mike Matson | Buy | 17 Aug 2026 | 58.00 USD |
| Oppenheimer | Suraj Kalia | Buy | 13 Oct 2026 | 60.00 USD |
| Weiss Ratings | Unnamed analyst | — | 15 Oct 2026 | — |
| Data feed RESEARCH | Research Team | Hold | 15 Jun 2026 | — |
Partial coverage · checked 6 Nov (6 Nov 2026, 03:07 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.